Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (NCT07347626) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
China786 participantsStarted 2026-03-01
Plain-language summary
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years.
✓. Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours.
✓. NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required.
✓. Presence of any of the following conditions after completion of standard intravenous thrombolysis:
✓. No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline).
✓. Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline).
✓. Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis).
✓. Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis.
Exclusion criteria
✕. Intracranial hemorrhage confirmed by CT or MRI.
✕. Planned endovascular therapy.
✕. Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction \< 30%.